Evidence map›Paper›PMID 42041716›Full record

ReviewCurrent oncology (Toronto, Ont.)2026

Preclinical Rationale, Clinical Efficacy, and Safety of the Selective AKT Kinase Inhibitor Capivasertib in Metastatic Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Carcinoma: A Practical Narrative Review.

Maria Rosaria Valerio, Daniela Sambataro, Federica Martorana, Martina Greco, Chiara Mesi, Vittorio Gebbia, Paolo Vigneri, Giuseppa Scandurra

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Current oncology (Toronto, Ont.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Maria Rosaria ValerioMedical Oncology Unit, Policlinico, University of Palermo, 90100 Palermo, Italy.
Daniela SambataroMedical Oncology, Ospedale Umberto I, 94100 Enna, Italy.ORCID 0009-0008-3909-9833
Federica MartoranaMedical Oncology, University of Catania, 95121 Catania, Italy.ORCID 0000-0001-5062-2914
Martina GrecoMedical Oncology Unit, Policlinico, University of Palermo, 90100 Palermo, Italy.
Chiara MesiMedical Oncology Unit, Policlinico, University of Palermo, 90100 Palermo, Italy.ORCID 0009-0000-4445-3288
Vittorio GebbiaMedical Oncology, University of Enna Kore, 94100 Enna, Italy.ORCID 0000-0001-8406-9416
Paolo VigneriMedical Oncology, University of Catania, 95121 Catania, Italy.ORCID 0000-0002-5943-6066
Giuseppa ScandurraMedical Oncology, University of Enna Kore, 94100 Enna, Italy.ORCID 0000-0001-8025-581X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Most patients with advanced/metastatic hormone receptor-positive, HER2-negative breast cancer receive first-line therapy with cycline-dependent kinase 4/6 inhibitors plus endocrine therapy. Almost universally, these patients eventually progress due to the emergence of resistant cancer clones. Targeting the PIK3CA/AKT1/PTEN pathway is a way of overcoming resistance. Recently, the oral, selective AKT kinase inhibitor capivasertib has been approved for the treatment of estrogen receptor-positive/human HER2-growth factor receptor-2 advanced BC with alterations in PIK3CA/AKT1/PTEN, in combination with fulvestrant after progression on endocrine therapy. We performed a narrative review to recapitulate the available evidence about capivasertib in the management of advanced hormone receptor-positive, HER2-negative breast cancer, focusing on studies that address preclinical rationale, pharmacology, and clinically relevant problems.

Indexed as

Breast NeoplasmsProtein Kinase InhibitorsProto-Oncogene Proteins c-aktPyrimidinesPyrrolesAnimalsErb-b2 Receptor Tyrosine KinasesFemaleHumansReceptors, EstrogencapivasertibERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesProtein Kinase InhibitorsProto-Oncogene Proteins c-aktPyrimidinesPyrrolesReceptors, EstrogenAKTcapivasertibfulvestranthormone positive breast cancermTORPI3KPTEN

Identifiers

PMID42041716
PMCPMC13114317

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.